Floatz logo

1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione

Mitochondrial Metabolism Disorders

Kenneth Myers, MDSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Mitochondrial Metabolism Disorders cohort.

Asset / SponsorPhaseRating
Pioglitazone
The University of Texas Health Science Center at San Antonio
Phase 4BB
Doxecitine
Kenneth Myers, MD
Phase 2CCC

Same molecule, other indications

1-(2-Deoxy-?-D-erythro-pentofuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione is also rated in:

5-nucleotidase syndromeDormant
B
Indicative ·
57 / 100
View asset →
mitochondrial diseaseDormant
CCC
Indicative ·
53 / 100
View asset →
mitochondrial encephalomyopathyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →